biondvax (nasdaq: bvxv) is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains. biondvax’s technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.
Company profile
Ticker
SCNI
Exchange
Website
CEO
Ron Babecoff
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BiondVax Pharmaceuticals Ltd.
SEC CIK
SCNI stock data
Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
16 Apr 24
EFFECT
Notice of effectiveness
14 Feb 24
CORRESP
Correspondence with SEC
9 Feb 24
UPLOAD
Letter from SEC
2 Feb 24
F-3
Shelf registration (foreign)
30 Jan 24
6-K
Report of Foreign Private Issuer
18 Jan 24
D
$1.69 mm in equity / options / securities to be acquired, sold $1.69 mm, 4 investors
12 Jan 24
6-K
Report of Foreign Private Issuer
9 Jan 24
6-K
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
4 Jan 24
424B3
Prospectus supplement
2 Jan 24
Transcripts
Latest ownership filings
SC 13D
STONE DANIEL E.
12 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
STONE DANIEL E.
24 Jan 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
SC 13G/A
STONE DANIEL E.
6 Feb 23
3/A
YAEL MARGOLIN
23 Jan 23
3/A
Morris C Laster
23 Jan 23
3/A
George Lowell
23 Jan 23
3/A
Avner Rotman
23 Jan 23
3
Samuel J Moed
5 Jan 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.93 mm | 10.93 mm | 10.93 mm | 10.93 mm | 10.93 mm | |
Cash burn (monthly) | (no burn) | 1.06 mm | 265.50 k | 1.02 mm | 254.92 k | |
Cash used (since last report) | n/a | 13.55 mm | 3.39 mm | 13.01 mm | 3.25 mm | |
Cash remaining | n/a | -2.63 mm | 7.54 mm | -2.09 mm | 7.67 mm | |
Runway (months of cash) | n/a | -2.5 | 28.4 | -2.0 | 30.1 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 12 |
Opened positions | 7 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 866.31 mm |
Total shares | 171.18 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Nacht Marius | 170.96 mm | $557.34 mm |
Sabby Management | 190.93 k | $269.21 mm |
Millennium Management | 11.58 k | $15.75 mm |
Susquehanna International | 10.92 k | $14.85 mm |
Rhumbline Advisers | 3.50 k | $4.76 mm |
MS Morgan Stanley | 2.18 k | $3.08 mm |
Credit Agricole S A | 424.00 | $598.00 k |
UBS UBS Group AG - Registered Shares | 306.00 | $431.00 k |
Aspire Private Capital | 160.00 | $226.00 k |
Global Retirement Partners | 50.00 | $71.00 k |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
Scinai Immunotherapeutics' CDMO Unit And Ayana Pharma Signed A Five-Year Master Service Agreement to Provide Drug Development and cGMP Manufacturing Services
8 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Mar 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
7 Feb 24
Press releases
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
8 Apr 24
Scinai leadership to attend BIO-Europe Spring 2024
12 Mar 24
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
29 Feb 24
Scinai Welcomes Liat Halpert as Head of Business Development and Sales
13 Feb 24
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
25 Jan 24